Search research articles
Contact Us
Filters
Showing results (231-240 of 247) with videos related to
Page
of 25
Sort By:
Antimicrobial Agents and Chemotherapy
|
July 18, 2012
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model
Zakuan Z Deris, Heidi H Yu, Kathryn Davis, et al.
International Journal of Antimicrobial Agents
|
April 1, 2024
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing
Siobhonne K J Breen, Marina Harper, Carla López-Causapé, et al.
The Lancet. Microbe
|
June 25, 2026
Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations
Siobhonne K J Breen, Sara Cortés-Lara, Jessica R Tait, et al.
Journal of Clinical Pharmacology
|
December 4, 2024
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients
Joshua A Reeder, C Buddy Creech, Roger L Nation, et al.
The Journal of Antimicrobial Chemotherapy
|
September 17, 2016
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii
Justin R Lenhard, Jürgen B Bulitta, Terry D Connell, et al.
International Journal of Antimicrobial Agents
|
June 24, 2020
Transcriptomic responses of a New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol
Nusaibah Abdul Rahim, Soon-Ee Cheah, Matthew D Johnson, et al.
Antibiotics (Basel, Switzerland)
|
January 21, 2022
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
Jessica R Tait, Hajira Bilal, Kate E Rogers, et al.
The Journal of Infectious Diseases
|
September 30, 2024
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis
Stephanie L Rolsma, Andrew Sokolow, Pratish C Patel, et al.
ACS Infectious Diseases
|
April 9, 2021
Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo-β-Lactamase-Producing <i>Klebsiella pneumoniae</i> Is Predominately Driven by Chloramphenicol
Nusaibah Abdul Rahim, Yan Zhu, Soon-Ee Cheah, et al.
Pharmacotherapy
|
February 3, 2019
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T Tsuji, Jason M Pogue, Alexandre P Zavascki, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 247) with videos related to
Sort By:
Page
of 25
Antimicrobial Agents and Chemotherapy
|
July 18, 2012
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model
Zakuan Z Deris, Heidi H Yu, Kathryn Davis, et al.
International Journal of Antimicrobial Agents
|
April 1, 2024
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing
Siobhonne K J Breen, Marina Harper, Carla López-Causapé, et al.
The Lancet. Microbe
|
June 25, 2026
Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations
Siobhonne K J Breen, Sara Cortés-Lara, Jessica R Tait, et al.
Journal of Clinical Pharmacology
|
December 4, 2024
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients
Joshua A Reeder, C Buddy Creech, Roger L Nation, et al.
The Journal of Antimicrobial Chemotherapy
|
September 17, 2016
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii
Justin R Lenhard, Jürgen B Bulitta, Terry D Connell, et al.
International Journal of Antimicrobial Agents
|
June 24, 2020
Transcriptomic responses of a New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol
Nusaibah Abdul Rahim, Soon-Ee Cheah, Matthew D Johnson, et al.
Antibiotics (Basel, Switzerland)
|
January 21, 2022
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
Jessica R Tait, Hajira Bilal, Kate E Rogers, et al.
The Journal of Infectious Diseases
|
September 30, 2024
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis
Stephanie L Rolsma, Andrew Sokolow, Pratish C Patel, et al.
ACS Infectious Diseases
|
April 9, 2021
Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo-β-Lactamase-Producing <i>Klebsiella pneumoniae</i> Is Predominately Driven by Chloramphenicol
Nusaibah Abdul Rahim, Yan Zhu, Soon-Ee Cheah, et al.
Pharmacotherapy
|
February 3, 2019
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
Brian T Tsuji, Jason M Pogue, Alexandre P Zavascki, et al.
Page
of 25